Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs126372-   
Low Rs61268-   
Sales per share (Unadj.) Rs301.8110.6-  
Earnings per share (Unadj.) Rs-24.9-27.9-  
Cash flow per share (Unadj.) Rs2.5-23.1-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.386.8-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.7%   
Avg P/E ratio x-3.8-11.5 32.7%  
P/CF ratio (eoy) x36.7-13.9 -265.2%  
Price / Book Value ratio x0.33.7 8.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15454,029 2.1%   
No. of employees `0000.94.3 21.5%   
Total wages/salary Rs m3933,391 11.6%   
Avg. sales/employee Rs Th4,026.14,349.7 92.6%   
Avg. wages/employee Rs Th425.0789.9 53.8%   
Avg. net profit/employee Rs Th-331.8-1,096.0 30.3%   
INCOME DATA
Net Sales Rs m3,72418,673 19.9%  
Other income Rs m23131 17.2%   
Total revenues Rs m3,74718,804 19.9%   
Gross profit Rs m395-3,236 -12.2%  
Depreciation Rs m338806 42.0%   
Interest Rs m354506 70.0%   
Profit before tax Rs m-275-4,417 6.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32276 11.4%   
Profit after tax Rs m-307-4,705 6.5%  
Gross profit margin %10.6-17.3 -61.2%  
Effective tax rate %-11.5-6.2 183.7%   
Net profit margin %-8.2-25.2 32.7%  
BALANCE SHEET DATA
Current assets Rs m2,63813,677 19.3%   
Current liabilities Rs m2,3057,695 29.9%   
Net working cap to sales %8.932.0 27.9%  
Current ratio x1.11.8 64.4%  
Inventory Days Days135111 122.1%  
Debtors Days Days46124 37.4%  
Net fixed assets Rs m4,8717,972 61.1%   
Share capital Rs m12387 142.3%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,61914,656 24.7%   
Long term debt Rs m1,3745,151 26.7%   
Total assets Rs m7,50927,687 27.1%  
Interest coverage x0.2-7.7 -2.9%   
Debt to equity ratio x0.40.4 108.1%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %0.6-15.2 -4.2%  
Return on equity %-8.5-32.1 26.4%  
Return on capital %1.6-19.8 -8.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m5141,594 32.3%  
From Investments Rs m-123-489 25.2%  
From Financial Activity Rs m-3874,674 -8.3%  
Net Cashflow Rs m45,779 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.13 Rs / ZAR

Compare VENUS REMEDIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: CIPLA  AJANTA PHARMA  SUN PHARMA  AUROBINDO PHARMA  FDC  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

VENUS REMEDIES SHARE PRICE


Apr 9, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS